{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T08:13:42Z","timestamp":1769415222411,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 105-2314-B-002-186-MY3"],"award-info":[{"award-number":["MOST 105-2314-B-002-186-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2314-B-002-076-MY3"],"award-info":[{"award-number":["MOST 108-2314-B-002-076-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 111-2314-B-002-127-"],"award-info":[{"award-number":["MOST 111-2314-B-002-127-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 107-2314-B-002-199-"],"award-info":[{"award-number":["MOST 107-2314-B-002-199-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 108-2314-B-002-096-"],"award-info":[{"award-number":["MOST 108-2314-B-002-096-"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-002-268-"],"award-info":[{"award-number":["NSTC 112-2314-B-002-268-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2314-B-002-005-"],"award-info":[{"award-number":["NSTC 113-2314-B-002-005-"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-002-150 -"],"award-info":[{"award-number":["NSTC 112-2314-B-002-150 -"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2314-B-002 -206 -MY3"],"award-info":[{"award-number":["NSTC 114-2314-B-002 -206 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW111-TDU-B-221-114006"],"award-info":[{"award-number":["MOHW111-TDU-B-221-114006"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW112-TDU-B-222-124006"],"award-info":[{"award-number":["MOHW112-TDU-B-222-124006"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW113-TDU-B-221-134006"],"award-info":[{"award-number":["MOHW113-TDU-B-221-134006"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["MOHW114-TDU-B-221-144006"],"award-info":[{"award-number":["MOHW114-TDU-B-221-144006"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH 105\u2010N3333"],"award-info":[{"award-number":["NTUH 105\u2010N3333"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Taiwan University Cancer Center","award":["NTUCCS-111-06"],"award-info":[{"award-number":["NTUCCS-111-06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Esophagus"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Anti-PD-1 therapy plus chemotherapy (immunochemotherapy) has become standard first-line treatment for high PD-L1-expressing advanced esophageal squamous cell carcinoma (ESCC). Benefits of immunochemotherapy for low PD-L1-expressing ESCC remain debatable. The Cochrane, PubMed, and Embase databases were systemically searched from inception till 10 August 2024. Randomized trials comparing first-line immunochemotherapy with chemotherapy in ESCC were identified and evaluated association of platinum plus paclitaxel (TP) or fluoropyrimidine (PF) chemotherapy regimen, stratified by PD-L1 expression levels, with progression-free survival (PFS) and overall survival (OS) benefits. Pooled study-level hazard ratios (HRs) with 95% confidence intervals (CIs) for PFS and OS were calculated with a random-effects model. Eight studies involving 4733 participants were included. In high PD-L1 group, PFS (HR of TP: 0.56 [95% CI, 0.45\u20130.69] vs HR of PF: 0.53 [95% CI, 0.45\u20130.62]) and OS benefits (HR of TP: 0.60 [95% CI, 0.46\u20130.78] vs HR of PF: 0.59 [95% CI, 0.50\u20130.69]) did not significantly differ between two regimen subgroups (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.75 and 0.90, respectively). In low PD-L1 group, TP regimen was associated with a significantly greater PFS benefit than PF regimen (HR of TP: 0.59 [95% CI, 0.48\u20130.74] vs HR of PF: 0.82 [95% CI, 0.72\u20130.94];\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.01) and TP regimen trended to associate with greater OS benefit over PF regimen (HR of TP: 0.72 [95% CI, 0.55\u20130.93] vs HR of PF: 0.84 [95% CI, 0.72\u20130.97];\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.32). In patients with low PD-L1-expressing advanced ESCC, immunochemotherapy with TP may confer a greater PFS benefit than that with PF.\n                  <\/jats:p>","DOI":"10.1007\/s10388-025-01167-y","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T05:42:14Z","timestamp":1762753334000},"page":"25-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does chemotherapy regimen matter for first-line immunochemotherapy in low PD-L1-expressing esophageal squamous cell carcinoma? A systemic review and meta-analysis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6689-9640","authenticated-orcid":false,"given":"Jhe-Cyuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Shan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-Yi","family":"Shau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Yun","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Yang","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0495-973X","authenticated-orcid":false,"given":"Chih-Hung","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"issue":"3","key":"1167_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1167_CR2","doi-asserted-by":"crossref","unstructured":"Morgan E, Soerjomataram I, Rumgay H, et al. The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. 2022;163(3):649\u201358 e642.","DOI":"10.1053\/j.gastro.2022.05.054"},{"issue":"10","key":"1167_CR3","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/2159-8290.CD-12-0189","volume":"2","author":"N Agrawal","year":"2012","unstructured":"Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov. 2012;2(10):899\u2013905.","journal-title":"Cancer Discov"},{"issue":"7636","key":"1167_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541(7636):169\u201375.","journal-title":"Nature"},{"issue":"suppl 5","key":"1167_CR5","doi-asserted-by":"publisher","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","volume":"27","author":"F Lordick","year":"2016","unstructured":"Lordick F, Mariette C, Haustermans K, et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50\u20137.","journal-title":"Ann Oncol"},{"issue":"6","key":"1167_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/CAD.0b013e328051b3a3","volume":"18","author":"CC Lin","year":"2007","unstructured":"Lin CC, Yeh KH, Yang CH, et al. Multifractionated paclitaxel and cisplatin combined with 5-fluorouracil and leucovorin in patients with metastatic or recurrent esophageal squamous cell carcinoma. Anticancer Drugs. 2007;18(6):703\u20138.","journal-title":"Anticancer Drugs"},{"issue":"9","key":"1167_CR7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/jjco\/hye090","volume":"31","author":"K Hayashi","year":"2001","unstructured":"Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31(9):419\u201323.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"1167_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jfma.2019.10.010","volume":"119","author":"HY Kuo","year":"2020","unstructured":"Kuo HY, Guo JC, Hsu CH. Anti-PD-1 immunotherapy in advanced esophageal squamous cell carcinoma: a long-awaited breakthrough finally arrives. J Formos Med Assoc. 2020;119(2):565\u20138.","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"1167_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jfma.2022.05.009","volume":"122","author":"HY Kuo","year":"2023","unstructured":"Kuo HY, Guo JC, Hsu CH. Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: implications of positive phase III trials in advanced and resected esophageal cancer. J Formos Med Assoc. 2023;122(1):4\u20138.","journal-title":"J Formos Med Assoc"},{"issue":"11","key":"1167_CR10","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1167_CR11","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Xu J, Chen Y, et al. Camrelizumab versus investigator\u2019s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2020;21(6):832\u201342.","journal-title":"Lancet Oncol"},{"issue":"35","key":"1167_CR12","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138\u201348.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1167_CR13","doi-asserted-by":"publisher","first-page":"3065","DOI":"10.1200\/JCO.21.01926","volume":"40","author":"L Shen","year":"2022","unstructured":"Shen L, Kato K, Kim SB, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40(26):3065\u201376.","journal-title":"J Clin Oncol"},{"issue":"10302","key":"1167_CR14","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759\u201371.","journal-title":"Lancet"},{"issue":"suppl 3","key":"1167_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.250","volume":"42","author":"MA Shah","year":"2024","unstructured":"Shah MA, Sun JM, Shen L, et al. First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. J Clin Oncol. 2024;42(suppl 3):250.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1167_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386(5):449\u201362.","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"1167_CR17","doi-asserted-by":"publisher","first-page":"S161","DOI":"10.1016\/j.annonc.2024.05.313","volume":"35","author":"A Adenis","year":"2024","unstructured":"Adenis A, Chau I, Ajani JA, et al. 398P Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648. Ann Oncol. 2024;35(suppl 1):S161\u20132.","journal-title":"Ann Oncol"},{"issue":"9","key":"1167_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7235","volume":"13","author":"K Kato","year":"2024","unstructured":"Kato K, Doki Y, Chau I, et al. Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial. Cancer Med. 2024;13(9):e7235.","journal-title":"Cancer Med"},{"issue":"5","key":"1167_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","volume":"24","author":"J Xu","year":"2023","unstructured":"Xu J, Kato K, Raymond E, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24(5):483\u201395.","journal-title":"Lancet Oncol"},{"issue":"10","key":"1167_CR20","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1001\/jama.2021.12836","volume":"326","author":"H Luo","year":"2021","unstructured":"Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326(10):916\u201325.","journal-title":"JAMA"},{"issue":"9","key":"1167_CR21","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.medj.2024.05.008","volume":"5","author":"M He","year":"2024","unstructured":"He M, Wang Z, Lu J, et al. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial. Med. 2024;5(9):1137-49.e3.","journal-title":"Med"},{"key":"1167_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068714","volume":"377","author":"Z Lu","year":"2022","unstructured":"Lu Z, Wang J, Shu Y, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e068714.","journal-title":"BMJ"},{"issue":"suppl 8","key":"1167_CR23","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-CT075","volume":"83","author":"Z Lu","year":"2023","unstructured":"Lu Z, Wang J, Shu Y, et al. Abstract CT075: updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15). Cancer Res. 2023;83(suppl 8):CT075.","journal-title":"Cancer Res"},{"issue":"3","key":"1167_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","volume":"40","author":"ZX Wang","year":"2022","unstructured":"Wang ZX, Cui C, Yao J, et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell. 2022;40(3):277-88.e3.","journal-title":"Cancer Cell"},{"issue":"2","key":"1167_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41591-022-02179-2","volume":"29","author":"Y Song","year":"2023","unstructured":"Song Y, Zhang B, Xin D, et al. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial. Nat Med. 2023;29(2):473\u201382.","journal-title":"Nat Med"},{"issue":"3","key":"1167_CR26","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41591-024-02797-y","volume":"30","author":"J Li","year":"2024","unstructured":"Li J, Chen Z, Bai Y, et al. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study. Nat Med. 2024;30(3):740\u20138.","journal-title":"Nat Med"},{"issue":"10","key":"1167_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","volume":"33","author":"R Obermannova","year":"2022","unstructured":"Obermannova R, Alsina M, Cervantes A, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):992\u20131004.","journal-title":"Ann Oncol"},{"issue":"7","key":"1167_CR28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1200\/JCO.22.02331","volume":"41","author":"MA Shah","year":"2023","unstructured":"Shah MA, Kennedy EB, Alarcon-Rozas AE, et al. Immunotherapy and targeted therapy for advanced gastroesophageal cancer: ASCO guideline. J Clin Oncol. 2023;41(7):1470\u201391.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1167_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus. 2023;20(3):343\u201372.","journal-title":"Esophagus"},{"issue":"9","key":"1167_CR30","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1200\/JCO.22.01490","volume":"41","author":"HX Wu","year":"2023","unstructured":"Wu HX, Pan YQ, He Y, et al. Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis. J Clin Oncol. 2023;41(9):1735\u201346.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1167_CR31","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1001\/jamaoncol.2022.5816","volume":"9","author":"DWT Yap","year":"2023","unstructured":"Yap DWT, Leone AG, Wong NZH, et al. Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups. JAMA Oncol. 2023;9(2):215\u201324.","journal-title":"JAMA Oncol"},{"issue":"1","key":"1167_CR32","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1186\/s12885-023-11715-3","volume":"23","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhang S, Guo X, et al. PD-1 inhibitors combined with paclitaxel and cisplatin in first-line treatment of esophageal squamous cell carcinoma (ESCC): a network meta-analysis. BMC Cancer. 2023;23(1):1221.","journal-title":"BMC Cancer"},{"key":"1167_CR33","unstructured":"Liu Y, Ren Z, Yuan L, et al. Paclitaxel plus cisplatin vs. 5-fluorouracil plus cisplatin as first-line treatment for patients with advanced squamous cell esophageal cancer. Am J Cancer Res. 2016;6(10):2345\u201350."},{"key":"1167_CR34","doi-asserted-by":"publisher","first-page":"1353445","DOI":"10.3389\/fimmu.2024.1353445","volume":"15","author":"L Gao","year":"2024","unstructured":"Gao L, Tang L, Peng J, Hu Z, Yang J, Liu B. PD-1 inhibitor combined with chemotherapy for first-line treatment of esophageal squamous cell carcinoma patients with distant metastasis: a real-world retrospective study. Front Immunol. 2024;15:1353445.","journal-title":"Front Immunol"},{"issue":"3","key":"1167_CR35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3626","volume":"11","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov. 2012;11(3):215\u201333.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1167_CR36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59\u201373.","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"1167_CR37","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14737140.2022.2110470","volume":"22","author":"J Xu","year":"2022","unstructured":"Xu J, Bai Y, Li E, et al. Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systemic review. Expert Rev Anticancer Ther. 2022;22(9):981\u201398.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1167_CR38","doi-asserted-by":"crossref","unstructured":"Pape M, Visser PAJ, de Vos-Geelen, et al. Treatment patterns and survival in advanced unresectable esophageal squamous cell cancer: A population- based study. Cancer Sci. 2021;113(3):1038\u201346.","DOI":"10.1111\/cas.15262"},{"issue":"9","key":"1167_CR39","doi-asserted-by":"publisher","first-page":"6610","DOI":"10.3390\/curroncol29090519","volume":"29","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Song R, Jia Y, et al. Comparison of efficacy and safety of taxanes plus platinum and fluorouracil plus platinum in the first-line treatment of esophageal cancer: a systematic review and meta-analysis. Curr Oncol. 2022;29(9):6610\u201327.","journal-title":"Curr Oncol"},{"issue":"suppl 16","key":"1167_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.4058","volume":"41","author":"L Wang","year":"2023","unstructured":"Wang L, Guo JC, Chuang CH, et al. Concordance among the three commercially available PD-L1 assays for esophageal squamous cell carcinoma. J Clin Oncol. 2023;41(suppl 16):4058.","journal-title":"J Clin Oncol"}],"container-title":["Esophagus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10388-025-01167-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10388-025-01167-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T21:05:02Z","timestamp":1769375102000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10388-025-01167-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1167"],"URL":"https:\/\/doi.org\/10.1007\/s10388-025-01167-y","relation":{},"ISSN":["1612-9059","1612-9067"],"issn-type":[{"value":"1612-9059","type":"print"},{"value":"1612-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work is a review article summarizing published clinical trial results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}